Chromophobe Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor, Clear Cell Renal Cell Carcinoma, Kidney Oncocytoma, Papillary Renal Cell Carcinoma, Urothelial Carcinoma
Conditions
Brief summary
This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors.
Detailed description
PRIMARY OBJECTIVES: I. In tissue, to discover and validate DNA methylation markers (MDMs) for detection of malignant renal and urothelial tumors. II. In blood, to assess the accuracy of candidate MDMs from above for detection of malignant renal and urothelial tumors. OUTLINE: This is an observational study. Participants may undergo blood, urine, and tissue sample collection on study. Participants' medical records are also reviewed.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Sponsors
Mayo Clinic
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* CASE TISSUE: * Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, clear cell papillary RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma * Age \>= 18 years * CASE BLOODS AND URINE: * Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma * Age \>= 18 years * HEALTHY CONTROL BLOODS AND URINE: * Patients has undergone negative hematuria workups (defined as negative abdominal imaging and negative cystoscopy * Age \>= 18 years
Exclusion criteria
* CASE TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD) * The current target pathology is a recurrence * Patient has undergone any prior radiation therapy to target lesion prior to surgery * Patient has received chemotherapy class drugs in the 5 years prior to surgery * Patient has had any transplants prior to surgery * Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X * Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease * RENAL CONTROL TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD). * Patient has inflammation, atypia, or hyperplasia of the parenchyma * Patient has a current or past history of renal cancer. * Patient has undergone any prior radiation therapy to target lesion prior to surgery * Patient has received chemotherapy class drugs in the 5 years prior to surgery * Patient has had any transplants prior to surgery * Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X * Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease * UROTHELIAL CONTROL TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD) * Patient has inflammation, atypia, or hyperplasia of the urothelium * Patient has a current or past history of urothelial cancer * Patient has undergone any prior radiation therapy to target lesion prior to surgery * Patient has received chemotherapy class drugs in the 5 years prior to surgery * Patient has had any transplants prior to surgery * Patient has confirmed or presumed lynch * CASE BLOODS AND URINE: * Patient has known primary cancer outside of the kidney within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers) * Patient has had surgery to completely or partially remove current target pathology * Patient has undergone any prior radiation therapy to target lesion prior to plasma and urine collection * Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection * Patient has had any transplants prior to plasma and urine collection * Patient has confirmed or presumed lynch * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD) * HEALTHY CONTROL BLOODS AND URINE: * Patient has known primary cancer outside of the urothelium within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers) * Current target pathology is a recurrence * Patient has undergone prior radiation therapy in the 5 years prior to plasma and urine collection * Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection * Patient has had any transplants prior to plasma and urine collection * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD) * Patient has confirmed or presumed lynch * Gross urinary incontinence * Patient has undergone cystectomy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identify novel methylated DNA markers in tissue for malignant renal and urothelial tumors | Baseline (at enrollment) | Assessed by the number of markers identified using unbiased whole methylome sequencing (RRBS). Top candidates will be validated in independent tissue. Potential markers will have relatively low background and a false discovery rate 20%. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJohn B. Kisiel, MD
Mayo Clinic in Rochester
Outcome results
None listed